Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ATMEKSI vs ENTADFI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ATMEKSI (atazanavir/cobicistat) is a fixed-dose combination of atazanavir, an HIV-1 protease inhibitor that inhibits viral protease, preventing cleavage of viral polyproteins and resulting in immature non-infectious virions, and cobicistat, a pharmacokinetic enhancer that inhibits CYP3A, increasing atazanavir exposure.
Combination of a 5α-reductase inhibitor (finasteride) and a phosphodiesterase 5 inhibitor (tadalafil). Finasteride inhibits type II 5α-reductase, preventing conversion of testosterone to dihydrotestosterone, reducing prostate growth. Tadalafil inhibits PDE5, increasing c GMP in smooth muscle, causing relaxation of the prostate and bladder neck.
Treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg,Off-label use as part of antiretroviral therapy in treatment-experienced patients with viral suppression
Treatment of signs and symptoms of benign prostatic hyperplasia (BPH),Treatment of BPH in men with an enlarged prostate to improve symptoms, reduce risk of acute urinary retention, and reduce need for surgery
1.5 mg/kg IV every 4 weeks
5 mg orally once daily.
Terminal elimination half-life is 12 hours; renally impaired patients have prolonged half-life up to 24 hours.
Finasteride: terminal half-life ~6-8 hours (range 4-12 h) in young adults, 8 hours in elderly. Tadalafil: terminal half-life ~17.5 hours (range 11-28 h), supporting once-daily dosing.
Atazanavir is metabolized by CYP3A4; cobicistat is metabolized by CYP3A and to a minor extent by CYP2D6.
Finasteride is metabolized primarily via CYP3A4. Tadalafil is metabolized mainly by CYP3A4.
Primarily renal (80% unchanged) and biliary/fecal (15% as metabolites).
ENTADFI (finasteride 5 mg and tadalafil 5 mg) is a fixed-dose combination. Finasteride is excreted 57% in feces (as metabolites) and 39% in urine (<1% as unchanged). Tadalafil is excreted primarily as metabolites, with 61% in feces and 36% in urine; <0.001% of dose is excreted unchanged in urine.
95% bound to albumin and alpha-1-acid glycoprotein.
Finasteride: ~90% bound to plasma proteins (mainly albumin). Tadalafil: ~94% bound to plasma proteins (mainly albumin).
2.0 L/kg, indicating extensive tissue distribution.
Finasteride: Vd ≈ 76 L (approx 1.1 L/kg based on 70 kg). Tadalafil: Vd ≈ 63-77 L (approx 0.9-1.1 L/kg), indicating extensive tissue distribution.
Oral: 60-70% due to first-pass metabolism.
Finasteride 5 mg: oral bioavailability ~63% (range 56-74%). Tadalafil 5 mg: oral bioavailability ~80% (relative to intravenous); absorption not affected by food.
GFR 15-29 m L/min: 1.0 mg/kg IV every 4 weeks; GFR <15 m L/min: not recommended
No dose adjustment required for mild to moderate renal impairment. Not recommended in severe renal impairment (e GFR <30 m L/min/1.73 m²).
Child-Pugh A: no adjustment; Child-Pugh B: 1.0 mg/kg IV every 4 weeks; Child-Pugh C: not recommended
Contraindicated in Child-Pugh class B and C hepatic impairment. No dose adjustment required for Child-Pugh class A.
Age 2-17 years: 1.5 mg/kg IV every 4 weeks; maximum 120 mg per dose
Not approved for use in pediatric patients.
No specific adjustment; monitor renal function and reduce dose if GFR <30 m L/min
No specific dose adjustment required; however, monitor for adverse effects due to potential age-related renal and hepatic decline.
None
No FDA black box warning.
Hepatotoxicity, especially in patients with pre-existing liver disease or elevated transaminases,Nephrolithiasis and cholelithiasis,Cardiac conduction abnormalities (PR interval prolongation),Risk of developing resistance if not used with other antiretrovirals,Renal impairment (cobicistat decreases estimated creatinine clearance)
Hypersensitivity reactions,Sudden decrease in hearing or tinnitus,Prostate cancer screening and monitoring,Cardiovascular risk with sexual activity,Contraindicated with organic nitrates and GC stimulators (e.g., riociguat),Risk of priapism,Hepatic impairment dose adjustment,Renal impairment dose adjustment,Use of alpha-blockers,Antihypertensive effects,Risk of hypotension with concomitant alcohol
Concomitant use with drugs highly dependent on CYP3A for clearance (e.g., alfuzosin, rifampin, ergot derivatives, St. John's wort, lovastatin, simvastatin, sildenafil for pulmonary arterial hypertension),Severe hepatic impairment (Child-Pugh Class B or C)
Hypersensitivity to finasteride, tadalafil, or any component,Concurrent use of any organic nitrate,Concurrent use of guanylate cyclase stimulators (e.g., riociguat),Women, especially during pregnancy (finasteride teratogenicity)
Avoid alcohol (may exacerbate CNS effects). Grapefruit juice may increase atomoxetine exposure; limit consumption. High-fat meals do not significantly affect absorption.
Grapefruit juice may increase tadalafil plasma concentrations; avoid concurrent consumption. High-fat meals may delay tadalafil absorption but do not affect overall exposure. There are no significant food interactions with finasteride.
First trimester: Limited human data; animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: No known fetal risks. Avoid use during organogenesis unless benefit outweighs risk.
ENTADFI (finasteride and tadalafil) is contraindicated in pregnancy. Finasteride is a 5α-reductase inhibitor that inhibits conversion of testosterone to dihydrotestosterone (DHT) and can cause abnormal development of external genitalia in male fetuses. First trimester exposure is associated with hypospadias and other genital malformations. There is no human data for second and third trimester; however, based on mechanism, risks persist throughout pregnancy. Tadalafil, a PDE5 inhibitor, is Pregnancy Category B; no fetal harm is known in animals, but human data are limited.
Not recommended during breastfeeding. M/P ratio unknown. Excreted in animal milk; potential for serious adverse reactions in nursing infants.
No data available on ENTADFI (finasteride/tadalafil) in human milk. Finasteride is excreted in rat milk, but M/P ratio is unknown. Tadalafil is excreted in animal milk; M/P ratio unknown. Due to potential for adverse effects on lactating infant, especially from finasteride (possible interference with androgen metabolism), breastfeeding is not recommended during treatment and for at least 1 month after last dose.
No dose adjustment required in pregnancy. Pharmacokinetic profile unchanged.
ENTADFI is contraindicated in pregnancy; no dosing adjustments are recommended because use is not permitted. If inadvertently administered, discontinue immediately. There are no established pharmacokinetic changes in pregnancy for finasteride or tadalafil; however, pregnancy-induced changes in drug metabolism are not expected to alter the need for dose adjustment because the drug is not used during gestation.
ATMEKSI (atomoxetine) is a selective norepinephrine reuptake inhibitor (NRI) indicated for ADHD. It has a slower onset of action (2-4 weeks) compared to stimulants. Monitor for hepatotoxicity and suicidal ideation, especially in children and adolescents. Use cautiously with hepatic impairment (reduce dose) and CYP2D6 poor metabolizers (need lower dose). Avoid concurrent MAOIs. May cause orthostatic hypotension and urinary retention.
ENTADFI (finasteride and tadalafil fixed-dose combination) is used for benign prostatic hyperplasia (BPH). Finasteride reduces DHT, improving symptoms and reducing risk of acute urinary retention; tadalafil enhances smooth muscle relaxation via PDE5 inhibition. Monitor PSA levels during therapy (finasteride halves PSA). Assess cardiovascular status before initiating tadalafil; avoid concurrent nitrates. Caution in hepatic impairment (tadalafil exposure increased). Advise patients that therapeutic effect may take 3-6 months.
Take ATMEKSI exactly as prescribed; do not change dose without consulting your doctor.,It may take 2-4 weeks to notice improvement in symptoms.,Avoid alcohol and grapefruit juice as they may affect drug levels.,Report any signs of liver problems (yellowing of skin/eyes, dark urine, abdominal pain) or suicidal thoughts immediately.,May cause dizziness or fainting, especially when standing up; rise slowly.,Do not stop abruptly without medical advice.
Take ENTADFI at the same time daily with or without food.,Do not take more than one dose per day.,Avoid grapefruit juice as it may increase tadalafil levels.,Report sudden decrease in hearing or vision promptly.,Seek immediate medical help for erection lasting >4 hours.,Use contraception if partner is pregnant or may become pregnant (finasteride can cause fetal harm).,Do not donate blood during treatment and for 1 month after stopping.,Avoid alcohol excessively as it may increase risk of hypotension.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ATMEKSI vs ENTADFI, answered by our medical review team.
ATMEKSI is a PDE5 Inhibitor that works by ATMEKSI (atazanavir/cobicistat) is a fixed-dose combination of atazanavir, an HIV-1 protease inhibitor that inhibits viral protease, preventing cleavage of viral polyproteins and resulting in immature non-infectious virions, and cobicistat, a pharmacokinetic enhancer that inhibits CYP3A, increasing atazanavir exposure.. ENTADFI is a 5-Alpha Reductase Inhibitor and PDE5 Inhibitor that works by Combination of a 5α-reductase inhibitor (finasteride) and a phosphodiesterase 5 inhibitor (tadalafil). Finasteride inhibits type II 5α-reductase, preventing conversion of testosterone to dihydrotestosterone, reducing prostate growth. Tadalafil inhibits PDE5, increasing c GMP in smooth muscle, causing relaxation of the prostate and bladder neck.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ATMEKSI and ENTADFI depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ATMEKSI is: 1.5 mg/kg IV every 4 weeks. The standard adult dose of ENTADFI is: 5 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ATMEKSI and ENTADFI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ATMEKSI is classified as Category C. First trimester: Limited human data; animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: No known fetal risks. Avoid use during organogenesis u. ENTADFI is classified as Category C. ENTADFI (finasteride and tadalafil) is contraindicated in pregnancy. Finasteride is a 5α-reductase inhibitor that inhibits conversion of testosterone to dihydrotestosterone (DHT) a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.